
    
      a randomized, double-blind, placebo-controlled phase II multicenter trial is conducted to
      evaluate the efficacy and safety of mildronate injection in patients with acute ischemic
      stroke. patients will be randomized to receive a 14-day treatment of placebo or mildronate
      (500mg/5ml/each).Primary end-point is the modified Rankin scale at 3 monthes. Secondary
      end-point is the NIHSS scores and the Barthel index at 8 days and 15days. The safety
      end-point is defined as the incidence of adverse events, the change of Samples for routine
      laboratory tests and vital signs. Analysis is by intention to treat.
    
  